Skip to main content
. 2013 Jul 23;32(12):1805–1809. doi: 10.1007/s10067-013-2332-1

Table 2.

Cost per responder for infliximab combination therapy compared to conventional triple therapy

Response ACR20 ACR50 ACR70 EULAR (Good) EULAR (Moderate–good)
Cost per responder [€] 154,566 216,392 432,784 154,566 196,720
Cost per responder, VAT deducted [€] 130,225 182,315 364,629 130,225 165,741
Cost per responder, rebates deducted [€] 134,813 188,738 377,475 134,813 171,580
Cost per responder, VAT and rebates deducted [€] 110,472 154,660 309,321 110,472 140,600